Patient with NSCLC and brain metastases and positive reassortment ALK treated with alectinib - case report


MUDr. Leona Koubková

Pneumologická klinika 2. LF UK a FN v Motole, Praha



A better understanding of the molecular biology of tumors and the expanding possibilities of their genotyping lead to the enhancement of precise medicine, which is based on the pursuit of individualized treatment. It is primarily the genetic changes of the tumor that help us to predict the response to molecularly targeted treatment. These also include rearrangement of the ALK (anaplastic lymphoma kinase) gene in NSCLC (non-small cell lung cancer), which predicts the efficacy of ALK inhibitors, which significantly improve treatment outcomes in patients with this severe disease. Alectinib, the current standard for the first line ALK-positive NSCLC treatment, is a highly selective and potent inhibitor of ALK and RET (rearranged during transfection) tyrosine kinase and has been set to be reimbursed in the 1st line of treatment in the Czech Republic from 1st November 2019.


Key words

non-small cell lung cancer, ALK gene rearrangement, ALK inhibitors, alectinib, Alecensa



The full article is only available to subscribers

Become a regular subscriber to our Oncological Review...